Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Health

New Breakthrough Treatment for Triple-Negative Breast Cancer

Scientists in Australia believe they have made a significant breakthrough in the treatment of triple-negative breast cancer, the deadliest and most aggressive form of breast cancer. Unlike traditional chemotherapy, the new treatment specifically targets and slows the growth of cancerous cells within breast tissue, sparing healthy cells. This oral medication also addresses metastatic lesions that have spread to other parts of the body and have shown resistance to chemotherapy.

Triple-negative breast cancer, which constitutes up to 15 percent of all breast cancers, is notorious for its rapid growth and spread, particularly among young patients. Currently, there are no targeted drug treatments available for this type of cancer, leaving patients with limited options such as intensive chemotherapy or cutting-edge immunotherapy, both of which offer only modest success rates.

If the cancer metastasizes beyond the localized breast tissue, the five-year survival rate drops dramatically from 91 percent to 12 percent. Given the lack of effective treatments, there is an urgent need for new therapeutic approaches to combat this aggressive form of cancer.

According to breast cancer expert Theresa Hickey from the University of Adelaide, who led the experiments on the new oral medicine, this development represents a significant step forward in the fight against triple-negative breast cancer. Hickey stated, ‘The results of this study demonstrate that this drug could be the key to improving survival rates.’

The drug at the center of this breakthrough is CDDD11-8, which was initially designed to treat acute myeloid leukemia (AML). AML is a cancer that develops in the bone marrow and is challenging to target. The cancerous cells in AML thrive and spread by increasing protein production, particularly through a pathway known as cyclin-dependent kinase 9 (CDK9).

As of now, the United States Food and Drug Administration has not approved any drug that inhibits CDK9, although one version has shown promising initial clinical results. The potential of CDDD11-8 in treating triple-negative breast cancer offers hope for improving the survival rates of patients with this aggressive and difficult-to-treat form of the disease.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *